# US 2021/0330957 A1 · Use and monitoring of inhaled nitric oxide with left ventricular assist devices

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330957 A1
- Document ID: US20210330957A1
- Status: Published application
- Kind: A1
- Application number: 17/358,738
- Filed: 2021-06-25
- Published: 2021-10-28
- Earliest claimed: 2016-02-12
- Assignees: Mallinckrodt Pharmaceuticals Ireland Limited
- Applicants: Mallinckrodt Pharmaceuticals Ireland Limited
- Inventors: Jim Potenziano; Douglas Alan Greene; Craig Flanagan
- Web page: https://patentgrep.com/patent/US20210330957A1

## CPC

- A61M 60/148: in line with a blood vessel using resection or like techniques, e.g. permanent endovascular heart assist devices
- A61B 5/02007: {Evaluating blood vessel condition, e.g. elasticity, compliance}
- A61B 5/0215: by means inserted into the body
- A61B 5/029: Measuring blood output from the heart, e.g. minute volume
- A61B 5/4842: {Monitoring progression or stage of a disease}
- A61B 5/4848: {Monitoring or testing the effects of treatment, e.g. of medication}
- A61B 5/686: {Permanently implanted devices, e.g. pacemakers, other stimulators, biochips (A61B5/6861 takes precedence)}
- A61B 5/7275: {Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor}
- A61B 8/0883: {for diagnosis of the heart}
- A61M 60/178: drawing blood from a ventricle and returning the blood to the arterial system via a cannula external to the ventricle, e.g. left or right ventricular assist devices
- A61M 60/20: Type thereof
- A61M 60/515: Regulation using real-time patient data
- A61M 60/538: Regulation using real-time blood pump operational parameter data, e.g. motor current
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61B 5/0816: {Measuring devices for examining respiratory frequency (measuring frequency of electric signals G01R23/00)}
- A61M 2202/0275: Nitric oxide [NO]
- A61M 2205/05: combined with other kinds of therapy
- A61M 2205/3303: Using a biosensor
- A61M 2205/3553: remote, e.g. between patient's home and doctor's office
- A61M 2230/04: Heartbeat characteristics, e.g. ECG, blood pressure modulation
- G16H 20/40: relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
- G16H 50/30: for calculating health indices; for individual health risk assessment
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Described are systems and methods for administration of nitric oxide (NO) with use of left ventricular assists devices (LVADs), as well as systems and methods for monitoring the NO delivery devices and/or the LVAD.

## Claims

### Claim 1

A method of monitoring the left ventricle of a patient with a left ventricular assist device (LVAD), the method comprising:
reducing the pump speed of the LVAD or turning off the LVAD;
measuring one or more pulmonary hemodynamic parameters of the patient to obtain a first pulmonary hemodynamic value;
preloading the left ventricle by administering inhaled nitric oxide to the patient;
measuring one or more pulmonary hemodynamic parameters of the patient after or during administration of inhaled nitric oxide to obtain a second pulmonary hemodynamic value;
comparing the one or more hemodynamic parameters to a predetermined range; and
adjusting the dose of inhaled nitric oxide if the one or more hemodynamic parameters are outside of the predetermined range.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pulmonary hemodynamic parameter is selected from left atrial pressure (LAP), pulmonary capillary wedge pressure (PCWP) and cardiac output (CO).

### Claim 3 (depends on 1)

The method of claim 1, wherein the inhaled nitric oxide is administered at a concentration of 5 to 80 ppm for at least 10 minutes.

### Claim 4 (depends on 3)

The method of claim 3, wherein an increase in LAP and/or PCWP from the first pulmonary hemodynamic value to the second pulmonary hemodynamic value of less than 5 mm Hg indicates that the left ventricle is improving.

### Claim 5 (depends on 4)

The method of claim 4, further comprising modifying treatment if the left ventricle is improving, the modifying comprising explanting the LVAD from the patient.

### Claim 6 (depends on 4)

The method of claim 4, wherein preloading the left ventricle comprises administering inhaled nitric oxide at a concentration of 5 to 80 ppm for a time period in the range from 5 to 30 minutes, said preloading being performed between one and five times per day.

### Claim 7 (depends on 4)

The method of claim 4, further comprising exercising the heart, the exercising comprising:
discontinuing the inhaled nitric oxide administration; and
repeating the preloading and discontinuation to exercise the left ventricle of the patient's heart.

### Claim 8 (depends on 1)

The method of claim 1, wherein measuring one or more pulmonary hemodynamic parameters comprises monitoring one or more output parameters of the LVAD.
